Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time

Eli Lilly’s (LLY.N) powerful weight-loss drug Zepbound hit 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk’s (NOVOb.CO), opens new tab rival obesity medicine Wegovy for the first time since it was launched, according to data from IQVIA.